

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 7, 2022**

MARIMED INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

0-54433
(Commission
File Number)

27-4672745
(IRS Employer
Identification No.)

10 Oceana Way, Norwood, Massachusetts
(Address of principal executive offices)

02062
(Zip Code)

Registrant's telephone number, including area code: **(617) 795-5140**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None.

Title of each class
Not Applicable.

Ticker symbol(s)
Not Applicable.

Name of each exchange on which registered
Not Applicable.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(c) and (e): Effective September 7, 2022 (the "Effective Date"), MariMed Inc. (the "Company") promoted Jon Levine, Chief Administrative Officer of the Company, to President of the Company replacing Robert Fireman in that position (the "Promotion"). Mr. Fireman will continue in his roles as the Company's Chief Executive Officer and Chairman of the Board.

On the Effective Date, in connection and consistent with Mr. Levine's Promotion to the position of President of the Company, Mr. Levine's employment agreement with the Company was amended to change his title to President, and to reflect responsibilities and duties commensurate with that position. A copy of the form of the amendment to his employment agreement is attached as Exhibit 10.1 hereto.

Item 8.01. Other Events.

On the Effective Date, the Company issued a press release announcing the Promotion, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
10.1	Form of Third Amendment to Employment Agreement, effective as of September 7, 2022, between MariMed Inc. and Jon R. Levine.
99.1	Press Release dated September 7, 2022.
104	Cover Page Interactive Data File (embedded with the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARIMED INC.

Dated: September 7, 2022

By: /s/ Susan Villare
Susan Villare, Chief Financial Officer

MariMed Inc.

THIRD AMENDMENT TO EMPLOYMENT AGREEMENT

Effective Date: September 7, 2022

This Third Amendment to the Employment Agreement (this "Agreement") is between MARIMED INC., a Delaware corporation (the "Company" or "MariMed"), and JON R. LEVINE, an individual (the "Executive").

WHEREAS, the Company and the Executive entered into an Employment Agreement effective as of dated July 1, 2021, as amended by the First Amendment to Employment Agreement effective as of September 22, 2021 and the Second Amendment to Employment Agreement effective as of May 12, 2022, providing for the continued employment of the Executive (the "Original Agreement"); and

WHEREAS, the Company and the Executive seeks to amend the Original Agreement in accordance with the terms of this Agreement.

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. The Original Agreement is hereby amended as follows:

(a) Section 2(a) of the Original Agreement is hereby amended to change Executive's title, duties and responsibilities and as amended Section 2(a) shall read as follows:

"During the Term, the Executive will serve as the President of the Company. The Executive will have such duties and responsibilities, consistent with past practice, as are customary for the position of President and such other duties and responsibilities as are reasonably assigned to him by the Board of Directors of the Company (the "Board"). The Executive shall report to and be supervised by the Board."; and

(b) All references to "Chief Administrative Officer" are hereby amended and replaced with "President."

2. Except as otherwise amended by this Agreement, all other provisions of the Agreement shall remain in full force and effect.

[SIGNATURE PAGE FOLLOWS ON THE NEXT PAGE]

The undersigned hereby execute this Agreement as of the Effective Date stated above.

MARIMED INC.

By: */s/ Robert Fireman*

Robert Fireman
Chief Executive Officer

/s/ Jon R. Levine

Jon R. Levine



MariMed Appoints Jon Levine as President

NORWOOD, Mass., September 7, 2022 – MariMed, Inc. (CSE: MRMD), (OTCQX: MRMD) (“MariMed” or the “Company”), a leading multi-state cannabis operator (“MSO”) focused on improving lives every day, today announced the appointment of Jon Levine as President, effective immediately.

Mr. Levine co-founded MariMed with Chief Executive Officer Bob Fireman over a decade ago. The two executives, with current Chief Operating Officer Tim Shaw, built the foundation of the business that has grown to become a leader in the cannabis industry. Mr. Levine’s sound financial discipline as Chief Financial Officer enabled MariMed to continually deliver some of the best financial results among publicly traded MSOs. He was subsequently elevated to the position of Chief Administration Officer, with responsibility for the Company’s sales, marketing, operations, financial reporting, and communications functions.

“I am thrilled to announce Jon’s appointment as President of the Company, a role that includes his continued oversight of the day-to-day management of the Company,” said MariMed CEO Bob Fireman. “Jon will also assist me with our capital market activities and public appearances, enabling me to focus more on evolving our proven strategic and growth plans as the cannabis industry landscape continues to change.”

Mr. Fireman continued, “The consolidation in the cannabis industry and other factors have opened new opportunities for MariMed to expand and grow at an accelerated pace. With a deep and experienced management team, great brands, and a strong balance sheet, we are poised to seize these opportunities.”

“I am so proud of the Company that Bob and I have built, and the great team that has helped us achieve our success to date,” said MariMed President Jon Levine. “I look forward to our next chapter of the journey as President of MariMed.”

About MariMed

MariMed Inc., a multi-state cannabis operator, is dedicated to improving lives every day through its high-quality products, its actions, and its values. The Company develops, owns, and manages seed to sale state-licensed cannabis facilities, which are models of excellence in horticultural principles, cannabis cultivation, cannabis-infused products, and dispensary operations. MariMed has an experienced management team that has produced consistent growth and success for the Company and its managed business units. Proprietary formulations created by the Company’s technicians are embedded in its top-selling and award-winning products and brands, including *Betty’s Eddies*, *Nature’s Heritage*, *Bobby’s Baked*, *K Fusion*, *Kalm Fusion*, and *Vibations: High + Energy*. For additional information, visit www.marimedinc.com.

Investor Relations Contact:

Steve West
Vice President, Investor Relations
Email: ir@marimedinc.com
Phone: (781) 277-0007

Media Contact:

Trailblaze PR
Email: marimed@trailblaze.co

Company Contact:

Howard Schacter
Chief Communications Officer
Email: hschacter@marimedinc.com
Phone: (781) 277-0007

###
